According to the research report titled ‘United States Non-Invasive Prenatal Testing (NIPT) Market Size, Share, Emerging Trends, Current Analysis, Growth, Demand, Opportunity, and Forecast 2022 – 2030’, available with MarketStudyReport, United States non-invasive prenatal testing (NIPT) market accounted for USD 788 million in 2021 and is anticipated to expand at a CAGR of 13.9% over 2022-2030 to amass a valuation of USD 2557 million by the year 2030.

Report findings suggest that United States non-invasive prenatal testing (NIPT) market growth is attributed to rising occurrences of chromosomal aneuploidies among fetus, in consort with advancements as well as rising adoption in non-invasive prenatal testing methods.

Request sample copy of this report: https://www.marketstudyreport.com/request-a-sample/4751538/  

Furthermore, increasing focus on reimbursement, rising preference for non-invasive procedures over invasive methods, along with the recommendation of NIPT from ACOG (American College of Obstetricians and Gynecologists) for all pregnancies irrespective of risk are contributing towards industry expansion.

The study contains a complete assessment of several growth accelerators, restraints, and trends prevailing in the market. It will be used to conduct a 360-degree examination that fully integrates several models.

The study report of United States non-invasive prenatal testing (NIPT) industry also offers the most up-to-date information on comparative test analysis. Egg donor, twin, sex chromosomal aneuploidy, fetal fraction, starting week, accuracy, gender, technology, deletion/duplication, turnaround time, and triploidy are among the several factors which are discussed in the comparative test analysis.

Moreover, this  study analyses the most recent reimbursement patterns and provides a clear picture of the regulatory framework in the business sphere.

Speaking of the competitive arena, Quest Diagnostics, Inc., Ariosa Diagnostics, Inc., Myriad Genetics, Inc., Agilent Technologies, Inc., GenePath Diagnostics, PerkinElmer, Inc., Yourgene Health, Invitae Corporation, Centogene N.V., Natera, Inc., Illumina, Inc., and Laboratory Corporation of America Holdings are the major players in United States non-invasive prenatal testing (NIPT) market.

The study and examines competitive trends such as mergers and acquisitions, collaboration agreements, distribution channels, venture capital investment, exclusive & licensing agreements, and partnership agreements to help stakeholders in making informed decisions.